MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Warrant (NQ:LEXXW)

0.0012 UNCHANGED
Last Price Updated: 3:34 PM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Warrant

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Lexaria Receives Independent Review Board Approval for its Upcoming Human Oral Nicotine Study
Via ACCESSWIRE
News headline image
Lexaria's Human Clinical Hypertension Study a Success
Via ACCESSWIRE
News headline image
Lexaria Bioscience: Taking Aim at the $28 Billion Hypertension Market; Human Clinical Study Yields Remarkable Results
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Lexaria Welcomes Dr. Catherine Turkel to its Board of Directors
Via ACCESSWIRE
News headline image
Lexaria Receives New Patent in Mexico
Via ACCESSWIRE
News headline image
Lexaria Discusses Valuation Metrics for Biotech Industry
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Positive FDA Feedback Concerning Opening IND Program
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for Hypertension
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Hypertension Study Completes Dosing with No Serious Adverse Events
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria's DehydraTECH CBD Hypertension Study Dosing Complete With No Serious Adverse Events ↗
Lexaria Bioscience Corp. (NASDAQ: LEXX) (NASDAQ: LEXXW) revealed that dosing with Lexaria's DehydraTECH-processed CBD has been completed in its multi-week human clinical hypertension study HYPER-H21-4 
Via Benzinga
News headline image
Lexaria's DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events
KELOWNA, BC / ACCESSWIRE / July 27, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that... 
From Lexaria Bioscience Corp.
Via AccessWire
News headline image
Lexaria's DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Licensee Launches Ko Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
Via ACCESSWIRE
News headline image
Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
KELOWNA, BC / ACCESSWIRE / July 26, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Supply Chain
News headline image
Lexaria To Receive Third Patent Granted in Japan; Submits FDA Filing
KELOWNA, BC / ACCESSWIRE / July 14, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Nearing Start Date for Its Human Nicotine Study
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria's Human Nicotine Study Nearing Start Date
Lexaria is targeting the oral nicotine pouch category, one of the fastest growing segments of the nicotine industry. 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
News headline image
Cannadips is Expanding Internationally, Leveraging Lexaria's DehydraTECH
KELOWNA, BC / ACCESSWIRE / July 7, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that... 
From Lexaria Bioscience Corp.
Via AccessWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Strategic Manufacturing, License Agreements with BevNology
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria Signs Manufacturing and License Agreements with BevNology
KELOWNA, BC / ACCESSWIRE / June 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the... 
From Lexaria Bioscience Corp.
Via AccessWire
News headline image
Lexaria Grants License to AnodGen Bioceuticals
KELOWNA, BC / ACCESSWIRE / June 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the... 
From Lexaria Bioscience Corp.
Via AccessWire
News headline image
Lexaria Files Pre-IND Meeting Request Letter with U.S. FDA
KELOWNA, BC / ACCESSWIRE / June 6, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce it has... 
From Lexaria Bioscience Corp.
Via AccessWire
News headline image
Lexaria Grants Exclusive License to Premier Wellness Science Co., Ltd. for Strategic and Long-Term Partnership in the Japanese Market
KELOWNA, BC / ACCESSWIRE / June 2, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce a... 
From Lexaria Bioscience Corp.
Via AccessWire
News headline image
Lexaria Grants License to Valcon Medical for the European Market
KELOWNA, BC / ACCESSWIRE / June 2, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Cannabis
News headline image
Lexaria Announces 2022 Annual Meeting Results
KELOWNA, BC / ACCESSWIRE / June 1, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results of the... 
From Lexaria Bioscience Corp.
Via AccessWire
News headline image
Lexaria Bioscience (NASDAQ: LEXX) Secures Patent For DehydraTECH To Deliver Antivirals ↗
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures First-Ever Patent for DehydraTECH to Deliver Antiviral Drugs
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs
- 25th patent grant is Lexaria's first-ever patent for the enhanced delivery of antivirals KELOWNA, BC / ACCESSWIRE / April 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
News headline image
Lexaria Bioscience (NASDAQ: LEXX) Commences Its Most Comprehensive Study To Date ↗
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story